ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: This study indicated that LY3295668 inhibited the proliferation of all CML cell lines, including those that were resistant to ABL TKIs, such as ABL TKI-resistant K562 cells and Ba/F3 T315I cells, in a dose-dependent manner (Fig. 1B).